Juliano Riella, MD
Transplant Surgery · Atlanta, GANPI 1033569090
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Intuitive Surgical at 53.3% of the total. 2025 is the largest year on record at $10,712, more than ten times the $419 reported in 2022.
Across 48 payments — averaging $305.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Vertex$3K
- Davol Inc.$2K
- BD$1K
- Dilon Technologies, Inc.$311
What the payments were for
- Consulting fees$3,10021%
- Travel & lodging$3,75726%
- Food & beverage$1,40510%
- Education$6,37944%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 17 | $7,809 |
| Vertex | 1 | $3,100 |
| Davol Inc. | 20 | $2,090 |
| BD | 8 | $1,330 |
| Dilon Technologies, Inc. | 2 | $311 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$6,250
- Phasix Mesh$2,147
- Da Vinci Surgical System$1,302
- HemoBlast Bellows$311
How this compares
$14,640 in reported general payments places this provider in the 75th percentile of 29 transplant surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $39,772 |
| Valganciclovir Hcl | 108 | $16,939 |
| Atovaquone | 11 | $7,028 |
| Mycophenolate Mofetil | 16 | $1,457 |
| Nifedipine ErNifedipine | 87 | $1,136 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $825 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 157 | $733 |
| ValacyclovirValacyclovir Hcl | 11 | $353 |
| Prednisone | 115 | $346 |
| Carvedilol | 36 | $202 |
| Atorvastatin Calcium | 65 | $195 |
| Pantoprazole Sodium | 28 | $169 |
| Hydralazine Hcl | 14 | $142 |
| Isoniazid | 13 | $55 |
| Oxycodone Hcl | 13 | $27 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in Atlanta
- Nicole TurgeonAtlanta$130K
- Stuart KnechtleAtlanta$88K
- Allan KirkAtlanta$80K
- Andrew AdamsAtlanta$60K
- Evan WeitmanAtlanta$40K
- Clark KensingerAtlanta$35K
- Harrison PollingerAtlanta$9K
- Marty SellersAtlanta$4K
- Jonathan HundleyAtlanta$4K
- Steven KimAtlanta$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.